Ownership and insider activity for Citius Pharmaceuticals, Inc. (CTXR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
Price
| Price | $0.56 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-08-08 | Mazur Leonard L | A-Award | 125,490 | $3.6M |
| 2025-08-08 | Mazur Leonard L | A-Award | 89,388 | $1.7M |
| 2025-08-08 | Mazur Leonard L | D-Return | 89,388 | $1.7M |
| 2025-08-08 | Mazur Leonard L | D-Return | 125,490 | $3.6M |
| 2025-08-08 | HOLUBIAK MYRON Z | A-Award | 31,373 | $902K |
| 2025-08-08 | HOLUBIAK MYRON Z | A-Award | 22,344 | $430K |
| 2025-08-08 | HOLUBIAK MYRON Z | D-Return | 31,373 | $902K |
| 2025-08-08 | HOLUBIAK MYRON Z | D-Return | 22,344 | $430K |
| 2024-11-07 | Webb Carol | A-Award | 125,000 | $48K |
| 2024-11-07 | Smith Robert Joseph | A-Award | 125,000 | $48K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $294351 | $3.2M | $9.2M | $7.9M | $13.9M | $70.1M | $41.7M | $26.5M | $3.3M | $4.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $818343 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $8.3M | $22.3M |
| Total Current Assets | $892835 | $3.4M | $10.1M | $7.9M | $14.0M | $72.8M | $44.6M | $34.4M | $14.2M | $27.9M |
| Property, Plant & Equipment | $3742 | $3236 | $1483 | $590 | $987781 | $829851 | $650174 | $455858 | $246247 | $818694 |
| Goodwill | $1.6M | $1.6M | $1.6M | $1.6M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M |
| Intangible Assets | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $59.4M | $59.4M | $59.4M | $92.8M | $92.8M |
| Total Assets | $22.0M | $24.4M | $31.1M | $29.0M | $43.8M | $142.4M | $114.0M | $103.6M | $116.7M | $130.9M |
| Accounts Payable | $909156 | $602431 | $1.6M | $2.7M | $1.9M | $1.3M | $1.2M | $2.9M | $4.9M | $13.7M |
| Short-term Debt | $672970 | $172970 | $172970 | $172970 | $172970 | $177237 | 0 | 0 | 0 | $1.0M |
| Total Current Liabilities | $5.2M | $2.5M | $3.2M | $4.6M | $4.1M | $4.0M | $4.5M | $5.8M | $35.8M | $44.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | $164583 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $5.2M | $2.5M | $3.2M | $4.6M | $10.1M | $9.6M | $10.6M | $12.2M | $42.5M | $53.4M |
| Retained Earnings | -$17.3M | -$27.7M | -$40.3M | -$55.8M | -$70.6M | -$96.0M | -$129.7M | -$162.2M | -$201.4M | -$238.8M |
| Total Equity | $16.8M | $21.9M | $27.9M | $24.4M | $33.7M | $132.2M | $102.8M | $90.8M | $70.1M | $67.6M |
| Total Debt | $672970 | $172970 | $172970 | $172970 | $1.4M | $855471 | $678234 | $481245 | $262865 | $1.8M |
| Net Debt | $378619 | -$3.0M | -$9.0M | -$7.7M | -$12.5M | -$69.2M | -$41.0M | -$26.0M | -$3.0M | -$2.4M |
| Working Capital | -$4.3M | $955189 | $6.9M | $3.3M | $9.9M | $68.8M | $40.0M | $28.6M | -$21.6M | -$17.0M |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 0.84 |
Profitability
| Return on Equity | -67.15% |
| Return on Invested Capital | -67.62% |
| Return on Assets | -32.53% |
| Gross Margin | 19.97% |
| Operating Margin | -863.92% |
| Net Margin | -651.27% |
Related companies: ADTX · APLM · ATHA · CRIS · DARE · FBLG · ICU
Explore sector: Healthcare · Biotechnology
More sections of CTXR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks